New York, NY - July 12, 2012 (Investorideas.com Newswire)
Investorideas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues an alert for
Affymax, Inc. (NasdaqGS: AFFY),
trading at $13.30, gaining $1.34 or 11.20% as of 11:03AM EDT on over
1.5 Million shares. The stock had a morning high of $13.71 and is
currently the top percentage gainer on the NASDAQ.
The Company today reported that Takeda Pharmaceuticals America,
Inc. (TPA) has entered into a supply agreement for sourcing and supply
of OMONTYS (peginesatide) Injection to Fresenius Medical Care North
America and certain of its affiliates. OMONTYS is the only once-monthly
erythropoiesis-stimulating agent (ESA) for anemia available to the
dialysis patient population with chronic kidney disease (CKD) in the
United States.
About Affymax, Inc. (NasdaqGS: AFFY)
Affymax, Inc. is a biopharmaceutical company based in Palo Alto,
California. Affymax’s mission is to discover, develop and deliver
innovative therapies that improve the lives of patients with kidney
disease and other serious and often life-threatening illnesses. The
company’s first marketed product, OMONTYS, was approved by the U.S. Food
and Drug Administration (FDA) in March 2012. www.affymax.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector.
Sectors we cover include; water and renewable energy stocks, biotech
stocks, mining and gold stocks, energy stocks, natural gas stocks, tech
(includes cloud and social networking), defense stocks, nanotech, China
stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech and pharma stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. This site is currently compensated by featured
companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
No comments:
Post a Comment